Athena 1: A phase 1 study of REGN5837 in people with relapsed or refractory B-cell non-Hodgkin lymphomas
This is a phase 1 trial looking at an experimental treatment called REGN5837 in combination with another experimental drug called odronextamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs).
You can share the following ClinicalTrials.gov identifier with your medical team so they can find out more about the trial: NCT05685173
Trial aim and background
The aim of this trial is to find out how safe and well tolerated the medication REGN5837 is when given with another medication called odronextamab in patients with relapsed or refractory B-NHLs.
It is aiming to look at the side effects, how much medication is in the blood at certain times, whether the body makes antibodies to the medication and how well it works against the lymphoma.
This a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
Adults with CD20+ aggressive B-NHL which has progressed after at least 2 systemic treatments may be eligible for this trial.
Locations
Recruitment is taking place at the Royal Cornwall Hospitals NHS Trust, Truro.
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05685173
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.